John Vierling Net Worth

The estimated Net Worth of John Vierling is at least $122 Mille dollars as of 3 August 2022. John Vierling owns over 7,500 units of Athenex Inc stock worth over $7,065 and over the last 6 years he sold ATNX stock worth over $0. In addition, he makes $114,740 as Independent Director at Athenex Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

John Vierling ATNX stock SEC Form 4 insiders trading

John has made over 2 trades of the Athenex Inc stock since 2021, according to the Form 4 filled with the SEC. Most recently he exercised 7,500 units of ATNX stock worth $1,500 on 3 August 2022.

The largest trade he's ever made was exercising 7,500 units of Athenex Inc stock on 3 August 2022 worth over $1,500. On average, John trades about 788 units every 38 days since 2019. As of 3 August 2022 he still owns at least 35,325 units of Athenex Inc stock.

You can see the complete history of John Vierling stock trades at the bottom of the page.

John Vierling biography

Dr. John Moore Vierling M.D. is Independent Director of the Company, Dr. Vierling has served as a tenured Professor of Medicine and Surgery and Chief of Hepatology at the Baylor College of Medicine in Houston, Texas since 2005. He is also Director of Advanced Liver Therapies (a clinical research unit for adult liver diseases), Baylor Liver Health (a program for liver wellness) and Program Director of the Hepatology and Liver Transplantation Fellowship. He obtained his AB in Biology with Great Distinction from Stanford University and received his MD degree from Stanford University School of Medicine. He was the founding Medical Director of Liver Transplantation at both the University of Colorado Health Sciences Center and Cedars-Sinai/UCLA Medical Center, where he was Director of Hepatology beginning in 1990 and later Medical Director of Multi-Organ Transplantation. His clinical interests include autoimmune and alloimmune liver diseases, liver transplantation, hepatobiliary cancers, acute liver failure, viral hepatitis, non-alcoholic fatty liver disease, Wilson disease and drug-induced liver injury (“DILI”). His translational research interest is immunologic mechanisms of hepatobiliary injury in autoimmune and alloimmune liver diseases, cancer immunotherapy, DILI, viral hepatitis and acute liver failure. He has authored over 250 manuscripts, reviews and chapters. Honors include Phi Beta Kappa, Alpha Omega Alpha, Best Doctors in America, Top 1% physician rating by U.S. News and World Report, Who’s Who in America, Who’s Who in the World, Who’s Who in Science and Engineering and Who’s Who in Healthcare. He currently serves on the National Institutes of Health and National Institute of Diabetes and Digestive and Kidney Diseases Liver Tissue and Cell Distribution System Coordinating Committee and the DSMB for their DILI Network. He also has served as President of the American Association for the Study of Liver Diseases, Secretary-Treasurer of Digestive Disease Week® and chairman of the National board of directors of th

What is the salary of John Vierling?

As the Independent Director of Athenex Inc, the total compensation of John Vierling at Athenex Inc is $114,740. There are 13 executives at Athenex Inc getting paid more, with Johnson Lau having the highest compensation of $4,483,840.

How old is John Vierling?

John Vierling is 74, he's been the Independent Director of Athenex Inc since 2019. There are no older and 17 younger executives at Athenex Inc.

What's John Vierling's mailing address?

John's mailing address filed with the SEC is C/O ATHENEX, INC., 1001 MAIN STREET, SUITE 600, BUFFALO, NY, 14203.

Insiders trading at Athenex Inc

Over the last 7 years, insiders at Athenex Inc have traded over $33,215,399 worth of Athenex Inc stock and bought 5,920,005 units worth $73,651,360 . The most active insiders traders include Advisors Llcperceptive Life..., Song Yi Zhang e Song Yi Mandra Medical Ltd .... On average, Athenex Inc executives and independent directors trade stock every 12 days with the average trade being worth of $10,843. The most recent stock trade was executed by Joe Annoni on 22 February 2023, trading 625 units of ATNX stock currently worth $125.

What does Athenex Inc do?

athenex is a global specialty oncology pharmaceutical company focused on the development and commercialization of next generation therapies for cancer diseases and supportive therapies. the company is dedicated to delivering innovative drugs that can have a life-changing impact on cancer patients. our business includes medical technology innovation centers and a unique manufacturing supply chain across both china and north america. through the connected innovation and manufacturing supply chain presence, we can identify, develop and deliver proprietary medical technology across continents and multiple regulatory environments.

Complete history of John Vierling stock trades at Athenex Inc

Athenex Inc executives and stock owners

Athenex Inc executives and other stock owners filed with the SEC include:

• Johnson Lau,
  Chief Executive Officer and Chairman of the Board
• Rudolf Kwan,
  Chief Medical Officer
• Jeffrey Yordon,
  Chief Operating Officer and President, Athenex Pharmaceutical Division
• Randoll Sze,
  Chief Financial Officer
• Simon Pedder,
  Chief Business and Strategy Officer - Proprietary Products
• Jeffrey M. Yordon,
  COO & Pres of Athenex Pharmaceutical Division
• Dr. Rudolf Kwan M.D., M.B., B.S.,
  Chief Medical Officer
• Dr. Yiu-Nam Lau M.B.B.S., M.D., F.R.C.P., Ph.D.,
  Chairman & CEO
• Benson Tsang,
  Independent Director
• Stephanie Davis,
  Independent Director
• Kim Campbell,
  Lead Independent Director
• Jinn Wu,
  Independent Director
• Jordan Kanfer,
  Independent Director
• John Vierling,
  Independent Director
• Manson Fok,
  Director
• Robert Spiegel,
  Director
• Daniel Lang,
  Senior Director - Corporate Development, President - Axis Therapeutics Limited
• Tim McCarthy,
  IR Contact Officer
• William Zuo,
  President, China Division
• Dr. Wing-Kai Chan,
  Deputy Chief Medical Officer of Orascovery & Src Kinase Platforms
• John W. Matthei,
  VP of HR
• Caileigh Dougherty,
  Director of Investor Relations
• Michael Smolinski Ph.D.,
  Chief Scientific Officer
• Steven J. Adams,
  Interim Chief Accounting Officer
• Daniel Lang M.D.,
  Sr. Director of Corp. Devel.
• Jacqueline Li,
  Director of Corp. Devel. & Investor Relations
• Steven Rubis,
  Sr. Director of Investor Relations
• Teresa Brophy Bair,
  Gen. Counsel, Sr. VP of Admin. & Corp. Sec.
• Dr. Allen Barnett,
  Co-Founder & Pres Emeritus
• James Zukin,
  
• Michael D Cannon,
  
• J Nick Riehle,
  Chief Financial Officer
• Antony Leung,
  
• Song Yi Zhang,
  Director
• John Koh,
  Director
• Advisors Llcperceptive Life...,
  
• Sheldon Trainor Degirolamo,
  Director
• Timothy De Vere Cook,
  See Remarks
• Teresa Brophy Bair,
  General Counsel, SVP Admin.
• Joe Annoni,
  Chief Financial Officer
• Steven J. Adams,
  Interim Chief Acct Officer
• Michael Smolinski,
  Chief Scientific Officer